natgillin/translations-raw huggingface dataset:
The concomitant use of Karvea with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (glomerular filtration rate (GFR) &lt; 60 ml/min/1.73m2) (see sections 4.5 and 5.1).
Istodobna primjena lijeka Karvea s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of Karvea with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (glomerular filtration rate (GFR) &lt; 60 ml/min/1.73m2) (see sections 4.5 and 5.1).
Istodobna primjena lijeka Karvea s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1)..
The concomitant use of Kinzalkomb with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena Kinzalkomba s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of Kinzalmono with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) (see sections 4.5, and 5.1).
Istodobna primjena Kinzalmona s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of Micardis with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena Micardisa s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of MicardisPlus with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena MicardisPlusa s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolesti ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of MicardisPlus with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena MicardisPlusa s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of MicardisPlus with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena MicaridsPlusa s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of Neparvis with aliskiren-containing products is contraindicated in patients with diabetes mellitus or in patients with renal impairment (eGFR &lt; 60 ml/min/1.73 m2) (see section 4.3).
Istodobna primjena Neparvisa i lijekova koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolesti ili u bolesnika s oštećenjem bubrega (eGFR &lt; 60 ml/min/1,73 m2) (vidjeti dio 4.3).
The concomitant use of Pritor with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) (see sections 4.5, and 5.1).
Istodobna primjena Pritora s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of PritorPlus with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istovremena primjena PritorPlusa s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of Rasilamlo with an ACEI or an ARB is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena lijeka Rasilamlo s ACEI-ima ili ARB-ima kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of Rasilez HCT with an ACEI or an ARB is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena Rasilez HCT-a s ACEI-ima ili ARB-ima kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrežne funkcije (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of Rasilez with an ACEI or an ARB is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena Rasileza s ACEI-ima ili ARB-ima kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrežne funkcije (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of Sabervel with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena Sabervel s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of Telmisartan Actavis with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena lijeka Telmisartan Actavis s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of Telmisartan Teva Pharma with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena Telmisartana Teva Pharma s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove o 4.5 i 5.1.).
The concomitant use of Telmisartan Teva Pharma with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena Telmisartana Teva Pharma s lijekovima koji sadrže aliskiren kontrainidicrana je u bolesnika sa šećernom bolesti ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1.).
The concomitant use of Telmisartan Teva Pharma with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena Telmisartana Teva Pharma s lijekovima koji sadrže aliskirenom kontrainidirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of Telmisartan Teva with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena Telmisartana Teva s lijekovima koji sadrže aliskiren kontrainidicrana je u bolesnika sa šećernom bolesti ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove o 4.5 i 5.1.).
The concomitant use of Telmisartan Teva with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena Telmisartana Teva s lijekovima koji sadrže aliskiren kontrainidicrana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of Telmisartan Teva with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena Telmisartana Teva s lijekovima koji sadrže aliskiren kontrainidicrana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1.).
The concomitant use of telmisartan with aliskiren is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) (see sections 4.2, 4.4, 4.5).
Istodobna primjena telmisartana s aliskirenom je kontraindicirana kod bolesnika s dijabetes melitusom ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove 4.2, 4.4, 4.5).
The concomitant use of telmisartan with aliskiren is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) (see sections 4.2, 4.4, 4.5).
Istodobna primjena telmisartana s aliskirenom je kontraindicirana kod bolesnika s dijabetes melitusom ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove o 4.2, 4.4, 4.5).
The concomitant use of telmisartan/amlodipine with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena kombinacije telmisartan/amlodipin s lijekovima koji sadrže aliskiren kontrainidicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of telmisartan/amlodipine with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena kombinacije telmisartan/amlodipin s lijekovima koji sadrže aliskiren kontrainidicrana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of telmisartan/amlodipine with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) (see sections 4.5, and 5.1).
Istodobna primjena kombinacije telmisartan/amlodipin s lijekovima koji sadrže aliskiren kontrainidicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of Tolucombi with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena lijeka Tolucombi s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The concomitant use of Tolura with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Istodobna primjena lijeka Tolura s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR &lt; 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The corresponding frequency category for each adverse reaction is based on the following convention: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1000); very rare ( &lt; 1/10,000) and not known (cannot be estimated from the available data).
Odgovarajuće kategorije učestalosti za svaku nuspojavu temelje se na sljedećem načelu: vrlo često (≥1/10); često (≥1/100 i &lt; 1/10); manje često (≥1/1000 i &lt; 1/100); rijetko (≥1/10 000 i &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000) i nepoznato (ne može se procijeniti iz dostupnih podataka).
The corresponding percentages in integrated analysis of the 2 studies were 15.9% in vehicle group and 4.1% in NEVANAC group, p &lt; 0.001).
Odgovarajući postotci u integriranim analizama 2 ispitivanja bili su 15,9% u grupi s podlogom lijeka i 4,1% u grupi s lijekom NEVANAC, p &lt; 0,001).
The cumulative immunogenicity frequency to abatacept by the ECL assay with at least one positive sample in the short-term and long-term periods combined was 15.7% (215/1369) while on abatacept, with a mean duration of exposure of 48.8 months, and 17.3% (194/1121) after discontinuation ( &gt; 21 days up to 168 days after last dose).
Kumulativna učestalost frekvencije imunogenosti na abatacept dobivena ECL testom s barem jednim pozitivnim uzorkom u kratkotrajnom i dugotrajnom razdoblju bila je 15,7% (215/1369) tijekom primjene abatacepta, s prosječnim trajanjem izloženosti od 48,8 mjeseci, 17,3% (194/1121) nakon prekida primjene ( &gt; 21 dan do 168 dana nakon posljednje doze lijeka).
The cumulative immunogenicity frequency to abatacept by the ECL assay with at least one positive sample in the short-term and long-term periods combined was 15.7% (215/1369) while on abatacept, with a mean duration of exposure of 48.8 months, and 17.3% (194/1121) after discontinuation ( &gt; 21 days up to 168 days after last dose).
Kumulativna učestalost imunogenosti na abatacept dobivena ECL testom s barem jednim pozitivnim uzorkom u kombiniranom kratkotrajnom i dugotrajnom razdoblju zajedno bila je 15,7% % (215/1369) tijekom primjene abatacepta, s prosječnim trajanjem izloženosti od 48,8 mjeseci, a 17,3% (194/1121) nakon prekida primjene ( &gt; 21 dan do 168 dana nakon posljednje doze lijeka).
The cumulative incidence of serum aminotransferase abnormalities &gt; 3xULN in all Phase 2 and 3 studies (including respective open label extensions) was 17 of 483 subjects over a mean exposure duration of 79.5 weeks.
Kumulativna incidencija abnormalnosti serumskih aminotransferaza veća od 3 puta iznad gornje granice normale u fazi 2 i 3 ispitivanja (uključujući i otvorene produžetke ispitivanja), bila je od 483 ispitanika, tijekom izloženosti srednjeg trajanja 79,5 tjedana.
The cumulative renal excretion of total orlistat-related materials was &lt; 2 % of the given dose.
Kumulativno bubrežno izlučivanje tvari povezanih s orlistatom bilo je &lt; 2 % primijenjene doze.
The cumulative renal excretion of total orlistat-related materials was &lt; 2% of the given dose.
Kumulativno izlučivanje ukupnog materijala povezanog s orlistatom putem bubrega iznosilo je &lt; 2 % primjenjene doze.
The cumulative response rate curves (time to vitreous haze score of 0) were significantly different for the OZURDEX group compared to the Sham group (p &lt; 0.001), with patients receiving dexamethasone showing an earlier onset and greater treatment response.
Kumulativne stope odgovora (vrijeme do nultog stupnja zamućenja staklastog tijela) bile su značajno drukčije u skupini lijeka OZURDEX u usporedbi sa skupinom s placebo postupkom (p &lt; 0,001), a bolesnici koji su primali deksametazon pokazali su raniji početak i veći odgovor na liječenje.
The dabigatran trough concentrations were about 20 % lower in patients with a body weight &gt; 100 kg compared with 50-100 kg.
Minimalne koncentracije dabigatrana bile su oko 20 % niže u bolesnika s tjelesnom težinom &gt; 100 kg u usporedbi s 50 - 100 kg.
The dabigatran trough concentrations were about 20 % lower in patients with a body weight &gt; 100 kg compared with 50-100 kg.
Minimalne koncentracije dabigatrana bile su oko 20 % niže u bolesnika s tjelesnom težinom &gt; 100 kg u usporedbi s 50-100 kg.
The daily dose of ribavirin is weight based ( &lt; 75 kg = 1,000 mg and ≥ 75 kg = 1,200 mg) and administered orally in two divided doses with food; also refer to the Summary of Product Characteristics of ribavirin.
Dnevna doza ribavirina temelji se na tjelesnoj težini ( &lt; 75 kg = 1,000 mg i ≥ 75 kg = 1,200 mg) i primjenjuje se peroralno u dvije podijeljene doze uz obrok; također vidjeti sažetak opisa svojstava lijeka za ribavirin.
The data below summarizes the frequencies of the adverse reactions that were recorded following vaccination during clinical trials and worldwide post-marketing experience, using the following convention: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1000); very rare ( &lt; 1/10,000), not known (cannot be estimated from available data).
Dolje navedeni podaci sažeto prikazuju učestalost nuspojava koje su zabilježene nakon cijepljenja tijekom kliničkih ispitivanja i postmarketinške primjene širom svijeta, prema sljedećim kategorijama: vrlo često ( ≥ 1/10); često ( ≥ 1/100 do &lt; 1/10); manje često ( ≥ 1/1 000 do &lt; 1/100); rijetko ( ≥ 1/10 000 do &lt; 1/1 000); vrlo rijetko ( &lt; 1/10 000); nepoznato (ne može se utvrditi iz dostupnih podataka).
The DCR (complete response or partial response or stable disease) was significantly higher in patients treated with Lonsurf (44% vs 16%, p &lt; 0.0001).
Stopa kontrole bolesti (DCR, bolesnici s potpunim odgovorom, djelomičnim odgovorom ili stabilnom bolesti) je bila značajno viša u bolesnika liječenih Lonsurfom (44% naspram 16%, p &lt; 0,0001).
The decision to extend therapy to one year of treatment should be based on prognostic factors (e.g., genotype, age &gt; 40 years, male gender, bridging fibrosis).
Odluku o produljenju liječenja na godinu dana treba temeljiti na prognostičkim čimbenicima (npr. genotip, dob &gt; 40 godina, muški spol, premoštavajuća fibroza).
The decline in 6MWT distance from Baseline to Week 72 was significantly reduced compared with placebo in study PIPF-006 (p &lt; 0.001, rank ANCOVA).
U ispitivanju PIPF-006, smanjenje udaljenosti prijeđene tijekom 6MWT testa od početnih vrijednosti do onih izmjerenih u 72. tjednu bilo je značajno manje u odnosu na placebo (p &lt; 0,001, rang ANCOVA).
The decrease of susceptibility in vitro is subtle requiring two or more TAMs (generally M41L and T215Y) before stavudine susceptibility is decreased ( &gt; 1.5 fold).
Smanjenje osjetljivosti in vitro izrazito je blago, pa su potrebne dvije ili više TAM (općenito M41L i T215Y) da bi se smanjila osjetljivost na stavudin ( &gt; 1,5 puta).
The degree of renal impairment was defined according to baseline creatinine clearance (CrCl) (normal renal function when CrCl &gt; 80 mL/min; mild impairment with CrCl = 50-79 mL/min; moderate impairment with CrCl = 30-49 mL/min and severe impairment with CrCl = 10-29 mL/min).
Stupanj oštećenja funkcije bubrega definiran je prema početnom klirensu kreatinina (CrCl) (normalna funkcija bubrega kada je CrCl &gt; 80 mL/min; blago oštećenje uz CrCl = 50-79 mL/min; umjereno oštećenje uz CrCl = 30-49 mL/min i teško oštećenje uz CrCl = 10-29 mL/min).
The degree of renal impairment was defined according to baseline creatinine clearance (normal renal function when creatinine clearance &gt; 80 ml/min; mild impairment with creatinine clearance=50 to 79 ml/min; moderate impairment with creatinine clearance=30 to 49 ml/min and severe impairment with creatinine clearance=10 to 29 ml/min).
Stupanj oštećenja funkcije bubrega definiran je prema početnom klirensu kreatinina (normalna funkcija bubrega kada je klirens kreatinina &gt; 80 ml/min; blago oštećenje uz klirens kreatinina = 50 do 79 ml/min; umjereno oštećenje uz klirens kreatinina = 30 do 49 ml/min i teško oštećenje uz klirens kreatinina = 10 do 29 ml/min).
The denominator for relapse is the number of patients with HCV RNA &lt; LLOQ at their last on-treatment assessment.
Nazivnik za relaps je broj pacijenata s HCV RNK &lt; LLOQ na njihovom posljednjem pregledu za vrijeme trajanja liječenja.
The denominator for relapse is the number of patients with HCV RNA &lt; LLOQ at their last on-treatment assessment.
Nazivnik za relaps je broj pacijenata s HCV RNK &lt; LLOQ na njihovom posljednjem pregledu za vrijeme trajanja terapije.
The denominator for relapse is the number of subjects with HCV RNA &lt; LLOQ at their last on-treatment assessment.
Nazivnik za relaps je broj ispitanika s HCV RNK &lt; donje granice kvantifikacije na njihovom posljednjem pregledu za vrijeme trajanja terapije.
The denominator for relapse is the number of subjects with HCV RNA &lt; LLOQ at their last on-treatment assessment.
Nazivnik za relaps je broj ispitanika s HCV RNK &lt; LLOQ na njihovom posljednjem pregledu za vrijeme trajanja terapije.
The denominator is the number of patients with HCV RNA &lt; 25 IU/ml at planned end of treatment or a missing HCV RNA assessment at planned end of treatment and HCV RNA &lt; 25 IU/ml during follow-up from planned end of treatment onwards.
Nazivnik je broj bolesnika s HCV RNK &lt; 25 IU/ml na planiranom kraju liječenja ili nedostatak HCV RNK procjene na planiranom kraju liječenja i HCV RNK &lt; 25 IU/ml tijekom praćenja od planiranog kraja liječenja nadalje.
The denominator when calculating the relapse rate represents the number of patients with end-of-treatment response (HCV RNA &lt; 25 IU/ml).
Nazivnik pri izračunu stope relapsa predstavlja broj bolesnika s odgovorom na kraju liječenja (HCV RNK &lt; 25 IU/ml).
The desired haemoglobin concentration level in two studies was &gt; 13 g/dl (8.1 mmol/l); in the remaining three studies it was 12 to 14 g/dl (7.5 to 8.7 mmol/l).
Željena razina koncentracije hemoglobina u dva ispitivanja bila je &gt; 13 g/dl (8,1 mmol/l); u preostala tri ispitivanja bila je 12 do 14 g/dl (7,5 do 8,7 mmol/l).
The difference between both vaccines in terms of percentage of subjects with OPA titres  8 was &lt; 5% for all serotypes in common, including 6B and 23F. Post-primary and post-booster OPA antibody geometric mean titres (GMTs) elicited by Synflorix were lower than those elicited by 7-valent Prevenar for the seven shared serotypes, except for serotype 19F.
Razlika između oba cjepiva u postotku cijepljenih s OPA titrima  8 bila je manja od 5% za sve zajedničke serotipove, uključujući 6B i 23F. Nakon primovakcinacije i docjepljivanja geometrijski srednji titri (engl. geometric mean titres, GMT) OPA protutijela postignuti uz Synflorix bili su niži od onih uz 7-valentni Prevenar za sedam zajedničkih serotipova, osim za serotip 19F.
The difference between Enbrel alone and methotrexate alone was also significant (p &lt; 0.05).
Također je značajna razlika između Enbrela u monoterapiji i metotreksata u monoterapiji (p &lt; 0,05).
The difference between etanercept alone and methotrexate alone was also significant (p &lt; 0.05).
Također je značajna razlika između etanercepta u monoterapiji i metotreksata u monoterapiji (p &lt; 0,05).
The difference between methylnaltrexone bromide 12 mg once daily and placebo of 1.6 RFBMs per week is statistically significant (p &lt; 0.001) and clinically meaningful.
Razlika između metilnaltreksonbromida u dozi od 12 mg jedanput dnevno i placeba u iznosu od 1,6 pražnjenja crijeva bez primjene dodatnog laksativa tjedno statistički je značajna (p &lt; 0,001) i klinički bitna.
The difference between the change from baseline for Feraccru compared to placebo at week 12 was 2.25 g/dL (p &lt; 0.0001).
Razlika u promjeni između početne vrijednosti za Feraccru u odnosu na placebo u 12. tjednu bila je 2,25 g/dL (p &lt; 0,0001).
The difference in clearance between Fabry patients ≥ 65 years and those &lt; 65 years was 20%, which was not considered clinically significant.
Razlika u klirensu između bolesnika s Fabryjevom bolešću ≥ 65 godina i onih &lt; 65 godina iznosila je 20 %, što se nije smatralo klinički značajnim.
The difference in ORR was 22.9 % (p-value &lt; 0.0001).
Razlika u ORR-u bila je 22,9% (p-vrijednost &lt; 0,0001).
The difference in OS between the two treatment arms was statistically significant (p &lt; 0.001).
Razlika u ukupnom preživljenju između dvije terapijske skupine bila je statistički značajna (p &lt; 0,001).